Jesús
San Miguel Izquierdo
Consultor Investigador
VU University Medical Center
Ámsterdam, HolandaPublicaciones en colaboración con investigadores/as de VU University Medical Center (9)
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
2018
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology, Vol. 28, pp. iv52-iv61
-
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network
Leukemia, Vol. 2017
-
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217
2014
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362
2011
-
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement
Leukemia, Vol. 25, Núm. 5, pp. 749-760
-
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Blood, Vol. 118, Núm. 17, pp. 4519-4529
2010
-
Current multiple myeloma treatment strategies with novel agents: A European perspective
Oncologist, Vol. 15, Núm. 1, pp. 6-25